0001437749-19-004739.txt : 20190313 0001437749-19-004739.hdr.sgml : 20190313 20190313092851 ACCESSION NUMBER: 0001437749-19-004739 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190313 DATE AS OF CHANGE: 20190313 EFFECTIVENESS DATE: 20190313 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Gila Therapeutics, Inc. CENTRAL INDEX KEY: 0001673503 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-334701 FILM NUMBER: 19677250 BUSINESS ADDRESS: STREET 1: 1712 HUMBOLT AVENUE SOUTH CITY: MINNEAPOLIS STATE: MN ZIP: 55403 BUSINESS PHONE: 612-805-9054 MAIL ADDRESS: STREET 1: 1712 HUMBOLT AVENUE SOUTH CITY: MINNEAPOLIS STATE: MN ZIP: 55403 D 1 primary_doc.xml X0708 D LIVE 0001673503 Gila Therapeutics, Inc. 5420 Highwood Dr W Minneapolis MN MINNESOTA 55436 612-805-9054 DELAWARE None None Corporation true 2014 Thomas J. Vasicek 5420 Highwood Dr W Minneapolis MN MINNESOTA 55436 Executive Officer Director Promoter Jon Freeman 5420 Highwood Dr W Minneapolis MN MINNESOTA 55436 Executive Officer Christopher de Souza 5420 Highwood Dr W Minneapolis MN MINNESOTA 55436 Director Richard Horan 5420 Highwood Dr W Minneapolis MN MINNESOTA 55436 Director Biotechnology Decline to Disclose 06b false 2019-03-04 false true true true false 0 2000000 314434 1685566 Total Offering Amount includes $1,000,000 equity offering, plus warrants to purchase up to 715,702 shares of Series A Preferred Stock at $1.39723 per share, which may never be exercised. false 3 0 0 0 false Gila Therapeutics, Inc. /s/ Thomas J. Vasicek Thomas J. Vasicek Chief Executive Officer 2019-03-11